Literature DB >> 11809162

GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats.

W Zhang1, B Slusher, Y Murakawa, K M Wozniak, T Tsukamoto, P F Jackson, A A F Sima.   

Abstract

AIMS/HYPOTHESIS: Hyperglutamatergic activity induced by ischemia is believed to underlie neuronal damage in a variety of neurological disorders, including neuropathic pain. Since ischemia is believed to be a prominent mechanism involved in diabetic polyneuropathy (DPN), we investigated the effect of the glutamate carboxypeptidase II (GCPII, EC #3.4-17.21; previously termed NAALADase), an enzyme responsible for the hydrolysis of the neuropeptide NAAG to NAA and glutamate, on the development of DPN in type 1 diabetic BB/Wor rats.
METHODS: Diabetic animals were treated with 10 mg/kg/day i.p. of the selective GCPII inhibitor GPI-5232 from onset of diabetes for 6 months. Hyperalgesia to thermal stimulation and nerve conduction velocity (NCV) were measured monthly. The effect on structural DPN was assessed by scoring of single, teased myelinated fibers, myelinated fiber morphometry and ultrastructural examination of C-fibers at 6 months.
RESULTS: GCPII inhibition showed significant but partial effects on hyperalgesia (p<0.001), nerve conduction slowing (p<0.01) axonal and nodal structural changes (p<0.001), small myelinated fiber atrophy, and degenerative changes of C-fibers.
CONCLUSIONS: GCPII inhibition has beneficial effects on hyperalgesia, nerve function, and structural degenerative changes in DPN, which are likely mediated by inhibition of ischemia-induced glutamate release.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11809162     DOI: 10.1016/s0022-510x(01)00670-0

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  20 in total

1.  The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693.

Authors:  J P van der Post; S J de Visser; M L de Kam; M Woelfler; D C Hilt; J Vornov; E S Burak; E Bortey; B S Slusher; T Limsakun; A F Cohen; J M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

Review 2.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

Authors:  C Bařinka; C Rojas; B Slusher; M Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 3.  Role of mitochondria in diabetic peripheral neuropathy: Influencing the NAD+-dependent SIRT1-PGC-1α-TFAM pathway.

Authors:  Krish Chandrasekaran; Muragundla Anjaneyulu; Joungil Choi; Pranith Kumar; Mohammad Salimian; Cheng-Ying Ho; James W Russell
Journal:  Int Rev Neurobiol       Date:  2019-06-08       Impact factor: 3.230

Review 4.  Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family.

Authors:  Joseph H Neale; Rafal T Olszewski; Daiying Zuo; Karolina J Janczura; Caterina P Profaci; Kaleen M Lavin; John C Madore; Tomasz Bzdega
Journal:  J Neurochem       Date:  2011-07-01       Impact factor: 5.372

5.  Novel substrate-based inhibitors of human glutamate carboxypeptidase II with enhanced lipophilicity.

Authors:  Anna Plechanovová; Youngjoo Byun; Glenda Alquicer; L'ubica Skultétyová; Petra Mlčochová; Adriana Němcová; Hyung-Joon Kim; Michal Navrátil; Ronnie Mease; Jacek Lubkowski; Martin Pomper; Jan Konvalinka; Lubomír Rulíšek; Cyril Bařinka
Journal:  J Med Chem       Date:  2011-10-11       Impact factor: 7.446

6.  Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor.

Authors:  N A Calcutt; J D Freshwater; A P Mizisin
Journal:  Diabetologia       Date:  2004-04       Impact factor: 10.122

7.  GCP II (NAALADase) inhibition suppresses mossy fiber-CA3 synaptic neurotransmission by a presynaptic mechanism.

Authors:  Emilio R Garrido Sanabria; Krystyna M Wozniak; Barbara S Slusher; Asaf Keller
Journal:  J Neurophysiol       Date:  2003-08-13       Impact factor: 2.714

8.  Glutamate carboxypeptidase inhibition reduces the severity of chemotherapy-induced peripheral neurotoxicity in rat.

Authors:  Valentina A Carozzi; Alessia Chiorazzi; Annalisa Canta; Rena G Lapidus; Barbara S Slusher; Krystyna M Wozniak; Guido Cavaletti
Journal:  Neurotox Res       Date:  2009-09-15       Impact factor: 3.911

9.  Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models.

Authors:  Ghanashyam D Ghadge; Barbara S Slusher; Amos Bodner; Mauro Dal Canto; Krystyna Wozniak; Ajit G Thomas; Camilo Rojas; Takashi Tsukamoto; Pavel Majer; Richard J Miller; Anna Liza Monti; Raymond P Roos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-22       Impact factor: 11.205

10.  Expression and distribution of 'high affinity' glutamate transporters GLT1, GLAST, EAAC1 and of GCPII in the rat peripheral nervous system.

Authors:  Valentina Alda Carozzi; Annalisa Canta; Norberto Oggioni; Cecilia Ceresa; Paola Marmiroli; Jan Konvalinka; Chiara Zoia; Mario Bossi; Carlo Ferrarese; Giovanni Tredici; Guido Cavaletti
Journal:  J Anat       Date:  2008-11       Impact factor: 2.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.